Abiopharma

🔍 Haas G Hunter IV (Director)

Company: Orchid Island Capital, Inc. (ORC)

Report Date: 2026-06-26

Detailed Transactions and Holdings:

• Acquired 3,031 shares of Common Stock (Direct)
  Date: 2026-06-26 | Code: M | equity_swap_involved: 0 | shares_owned_after: 138,715.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,193 shares of Common Stock at $6.86 per share (Direct)
  Date: 2026-06-26 | Code: F | equity_swap_involved: 0 | shares_owned_after: 137,522.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 3,032 shares of Performance Units (Derivative)
  Date: 2026-06-26 | Code: M | equity_swap_involved: 0 | shares_owned_after: 97,939.95 | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: These shares represent 1,842 shares of the Company's common stock issued upon the vesting of Performance Units awarded to the Reporting Person on April 13, 2023 pursuant to the Issuer's 2021 Equity Incentive Plan and 2022 Long Term Equity Incentive Compensation Plan, and 1,189 shares of the Company's common stock issued upon the vesting of Performance Units awarded to the Reporting Person on March 19, 2024 pursuant to the Issuer's 2021 Equity Incentive Plan and 2023 Long Term Equity Incentive Compensation Plan. Cash was paid in lieu of issuing fractional shares based on the closing price of the Company's common stock on June 25, 2026.
• F2: The Reporting Person disposed of these shares of the Company's common stock to the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of shares.
• F3: The price represents the closing price of the Company's common stock on June 25, 2026.